5-(5-methyl-2-(3-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one | 1236665-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 5-(5-methyl-2-(3-(morpholine-4-carbonyl)phenylamino)pyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one
• 英文别名: 5-[[5-methyl-2-[3-(morpholine-4-carbonyl)anilino]pyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one
• CAS: 1236665-70-5
• 化学式: C₂₃H₂₂N₆O₄
• 分子量: 446.465
• InChiKey: RQCFAKPGXYRXBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20100190770A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

  公开了化合物I的结构，含有这些化合物的组合物，以及在治疗需要调节JAK途径或抑制JAK激酶，特别是JAK 2和JAK3的情况下使用这些化合物和组合物的方法。
• Compositions and methods for inhibition of the JAK pathway
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2565193A1

  公开（公告）日：2013-03-06

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

  本文公开了式 I 的化合物、含有这些化合物的组合物，以及这些化合物和组合物用于治疗调节 JAK 通路或抑制 JAK 激酶（尤其是 JAK 2 和 JAK3）具有治疗作用的疾病的方法。
• COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP4009974A1

  公开（公告）日：2022-06-15
• METHOD OF TREATING MUSCULAR DEGRADATION
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20130310340A1

  公开（公告）日：2013-11-21

  A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such as may result from ventilation.
• US8324200B2
  申请人：——

  公开号：US8324200B2

  公开（公告）日：2012-12-04